Press release content from PR Newswire. The AP news staff was not involved in its creation.
China Customer Relations Centers, Inc. to Hold Extraordinary General Meeting of Shareholders
May 7, 2021 GMT
TAI’AN, China, May 7, 2021 /PRNewswire/ China Customer Relations Centers, Inc. (Nasdaq: CCRC) (the “Company”), a leading e-commerce and financial services business process outsourcing (“BPO”) service provider in China, today announced that it has called an extraordinary general meeting of shareholders (the “EGM”), to be held on June 18, 2021 at 9:00 a.m. (Beijing Time), at the Company’s office located at 1366 Zhongtianmen Dajie, Xinghuo Science and Technology Park, High-tech Zone, Taian City, Shandong Province, 271000, People’s Republic of China, to consider and vote on, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger (the “Merger Agreement”), dated March 12, 2021, by and among the Company, Taiyin
Isaac Dietrich benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Piedmont Lithium makes strong progress with first US greenfield lithium project in more than 50 years and moves closer to becoming US company
The company’s unique geographic proximity of resources, production operations and prospective customers positions it on the path to be among the most sustainable producers of lithium hydroxide in the world. Piedmont has 39.2 million tonnes of mineral resources grading 1.09% lithium in the world-class Carolina Tin Spodumene-Belt
Piedmont Lithium Ltd’s (ASX:PLL) (NASDAQ:PLL) (OTCMKTS:PDDTF) had an ‘eventful’ March quarter, according to president and CEO Keith Phillips who said the company was positioning itself to be the United States’ first greenfield lithium project in more than 50 years and moving closer becoming a US company.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Millendo Therapeutics, Inc. ( Millendo or the Company ) (NASDAQ: MLND) in connection with the proposed merger of the Company with privately-held clinical-stage oncology company Tempest Therapeutics, Inc. ( Tempest ). Under the terms of the merger agreement, the two companies will combine their businesses in an all-stock transaction that will result in one combined entity that will trade publicly on the Nasdaq Capital Market. At close of the transaction, Tempest shareholders are expected to own 81.5% of the newly-combined company, with Millendo stockholders owning only approximately 18.5%.